Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,598.00
Bid: 1,597.50
Ask: 1,598.00
Change: -20.00 (-1.24%)
Spread: 0.50 (0.031%)
Open: 1,608.00
High: 1,615.00
Low: 1,575.00
Prev. Close: 1,618.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London midday: Footsie advances as Barclays rebounds

Mon, 02nd Jul 2012 11:41

- Better-than-expected manufacturing data from Asia- Eurozone jobless rate at all-time high- UK manufacturing PMI beats forecastsLondon's blue-chip index held on to gains on Monday morning with Barclays leading the risers as it continues to rebound after last week's sharp falls.Economic data from Asia helped to lift sentiment early on: China's purchasing managers' index (PMI) fell from 50.4 to 50.2 last month, according to the National Bureau of Statistics and China Federation of Logistics and Purchasing, beating forecasts of around 49.9; while Japan's Tankan manufacturers' sentiment survey improved from minus four to minus one in the second quarter, compared to expectations of an unchanged reading. The Eurozone's unemployment rate rose to 11.1% in May, in line with estimates and the highest since the creation of the Eurozone, according to the latest data from the region's statistics office, Eurostat. In domestic news, UK manufacturing PMI rose from 45.9 to 48.6 in June, well ahead of expectations of 46.5. However, with the sector still contracting (readings below 50 points), the pressure is mounting for the Bank of England to ramp up its asset purchase programme on Thursday when it announces its July policy decision.FTSE 100: Barclays rebounds after recent sell-offBarclays, the bank which last week was given a £290m fine for manipulating interbank lending rates, was a high riser today after revealing that its Chairman Macrus Agius has resigned. After numerous calls for CEO Bob Diamond to follow in Agius's footsteps, Investec analyst Ian Gordon said this morning that investors should "back Bob" and take advantage of the stock's recent underperformance.Royal Bank of Scotland (RBS) was flat after Oriel Securities downgraded its rating on the stock to 'hold'. It was revealed at the weekend that the bank had sacked several traders last year over the alleged manipulation of LIBOR. Insurance group Aviva advanced after announcing that Lord Colin Sharman has retired as Chairman and has been replaced by John McFarlane.Pharmaceuticals giant GlaxoSmithKline rose after revealing positive results from four pivotal phase III studies for its once-daily COPD treatment. The company said that the results of the studies support its intention to commence global regulatory submissions for the treatment from the end of 2012. Sector peer AstraZeneca was flat despite saying that Bristol-Myers Squibb's acquisition of Amylin Pharmaceuticals will strengthen the leadership position of its diabetes alliance with Bristol-Myers in a "growing area of high unmet medical need". Astra will make a payment of $3.4bn in cash to Amylin once it becomes a wholly-owned subsidiary of Bristol-Myers. Serco, the international services company, rose after it signed an agreement to dispose of most of its operations in Germany in a transaction with the local management team. FTSE 250: SOCO jumps over 8%Oil and gas group SOCO International surged after entering into a 'conditional' agreement with Lizeroux Oil & Gas to acquire the 20% minority interest in SOCO Vietnam that the group does not already own. Insurance group Catlin fell after Jefferies downgraded the stock as part of its review into the European insurance industry: "With Catlin now close to our price target, we downgrade to 'hold' also noting higher end US windstorm exposure and a broadly untouched reinsurance deductible." FTSE 100 - RisersBarclays (BARC) 168.65p +3.56%Aviva (AV.) 281.90p +3.41%Petrofac Ltd. (PFC) 1,427.00p +2.81%Weir Group (WEIR) 1,571.00p +2.68%Whitbread (WTB) 2,071.00p +2.12%BP (BP.) 430.05p +1.92%Rio Tinto (RIO) 3,077.00p +1.92%Amec (AMEC) 1,021.00p +1.90%Prudential (PRU) 751.00p +1.76%WPP (WPP) 786.50p +1.75%FTSE 100 - FallersShire Plc (SHP) 1,782.00p -2.73%British Sky Broadcasting Group (BSY) 688.00p -1.22%Smith & Nephew (SN.) 630.00p -1.18%Vodafone Group (VOD) 177.45p -1.00%Admiral Group (ADM) 1,183.00p -0.76%Morrison (Wm) Supermarkets (MRW) 264.40p -0.64%Pearson (PSON) 1,259.00p -0.55%AstraZeneca (AZN) 2,838.00p -0.53%Next (NXT) 3,184.00p -0.47%Capital Shopping Centres Group (CSCG) 320.90p -0.34%FTSE 250 - RisersSoco International (SIA) 310.90p +7.43%Imagination Technologies Group (IMG) 499.50p +7.05%Fenner (FENR) 380.80p +5.40%Aquarius Platinum Ltd. (AQP) 48.11p +5.37%Kenmare Resources (KMR) 41.50p +5.06%Travis Perkins (TPK) 1,019.00p +5.00%Ashtead Group (AHT) 271.40p +4.42%Shanks Group (SKS) 79.25p +3.80%Smith (DS) (SMDS) 152.70p +3.60%Oxford Instruments (OXIG) 1,269.00p +3.42%FTSE 250 - FallersAvocet Mining (AVM) 81.00p -10.05%Ocado Group (OCDO) 75.40p -2.96%Halfords Group (HFD) 223.60p -2.44%Euromoney Institutional Investor (ERM) 731.00p -2.08%Spirit Pub Company (SPRT) 49.75p -1.97%Debenhams (DEB) 85.25p -1.45%Catlin Group Ltd. (CGL) 419.80p -1.34%Perform Group (PER) 395.00p -1.25%Ruspetro (RPO) 133.50p -1.18%Home Retail Group (HOME) 83.65p -1.18%FTSE TechMARK - RisersAsterand (ATD) 1.05p +13.51%Phytopharm (PYM) 6.20p +5.53%Timeweave (TMW) 21.00p +5.00%Hiwave Technologies (HIW) 1.50p +3.45%Gresham Computing (GHT) 61.00p +2.95%Electronic Data Processing (EDP) 43.50p +2.35%Oxford Biomedica (OXB) 2.40p +2.13%Kofax (KFX) 256.25p +2.09%NCC Group (NCC) 815.00p +2.07%Sepura (SEPU) 68.25p +1.87%FTSE TechMARK - FallersBATM Advanced Communications Ltd. (BVC) 14.00p -4.27%Emblaze Ltd. (BLZ) 51.60p -3.55%AEA Technology Group (AAT) 0.20p -2.44%Vectura Group (VEC) 76.00p -0.98%Skyepharma (SKP) 78.25p -0.95%Phoenix IT Group (PNX) 180.00p -0.83%Microgen (MCGN) 139.00p -0.71%Ricardo (RCDO) 340.00p -0.58%Psion (PON) 87.00p -0.57%Consort Medical (CSRT) 700.00p -0.57%
More News
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.